Fresenius Group Overview

Results Center

To archive

Q1/19 Results

Fresenius makes solid start to 2019 and confirms Group guidance
  • Fresenius Kabi with continued good growth in Q1/19

  • Helios Germany stabilized; Helios Spain with continued dynamic growth

  • Fresenius Medical Care with strong financial performance supported by agreements that materialized earlier than planned

  • Growth investments on track

  • Group guidance confirmed despite expected earnings dilution from NxStage

Selected Key Figures Q1/19

key figures

1 On a comparable basis

2 In constant currency

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA